Carcinoid Tumor: Clinical Trials

20 trials for Carcinoid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 4 unknown, 3 terminated, 2 recruiting. 20 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Completed 9, Unknown 4, Terminated 3, Recruiting 2, Withdrawn 2
Phase 27Completed 3, Unknown 2, Recruiting 1, Terminated 1

Follow Carcinoid Tumor: new trials by email Literature Review of Carcinoid Tumor trials Research Report on Carcinoid Tumor

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RYZ401 - GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Phase 1RecruitingRayzeBio, Inc.1042025-12-032026-11-03
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Lu-177-DOTATATE, Olaparib, Ga dotatate scanning - Gastroenteropancreatico Tumors, Neuroendocrine Tumors
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)562022-10-032026-10-16
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Ga-68-DOTA-TOC, Siemens PET/MR scanner, Standard Siemens Software - Small Bowel Carcinoid Tumor
Phase 1WithdrawnMassachusetts General Hospital2018-11-012019-06-21
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma
Phase 1WithdrawnVanderbilt-Ingram Cancer Center2017-12-012017-09-28
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
surufatinib - Tumors
Phase 1 / Phase 2CompletedHutchmed1302015-11-012024-07-10
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)
68Ga-DOTATOC PET - Neuroendocrine Tumors, Carcinoid Tumors
Phase 1TerminatedLale Kostakoglu712014-12-012017-05-03
GA-68 DOTA-TOC of Somatostatin Positive Malignancies
Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma
Phase 1 / Phase 2TerminatedUniversity of California, San Francisco3002014-06-232019-11-12
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. - Neuroendocrine, Neuroendocrine Tumor
Phase 1 / Phase 2UnknownOchsner Health System2502014-03-012014-01-17
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
68Ga-DOTATOC PET/CT - Neuroendocrine Tumors, Carcinoid Tumors
Phase 1 / Phase 2CompletedSue O'Dorisio2232012-02-212021-07-27
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients
TKM-080301 - Cancer, Neuroendocrine Tumors
Phase 1 / Phase 2CompletedArbutus Biopharma Corporation682010-12-012019-01-16
Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Pasireotide LAR followed by Pasireotide LAR + Everolimus, Everolimus followed by Pasireotide LAR + Everolimus - Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Phase 1CompletedNovartis Pharmaceuticals362010-11-012020-12-21
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
Proton Therapy - Non-small Cell Lung Cancer, Small Cell Lung Cancer
Phase 1TerminatedM.D. Anderson Cancer Center302010-07-162020-01-02
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
RAD001 (everolimus, Afinitor®) - Neuroendocrine Tumors, Carcinoid Tumor
Phase 1 / Phase 2UnknownGuangdong Provincial People's Hospital202010-07-012010-08-04
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
PV-10 (10% rose bengal disodium) - Cancer Metastatic to the Liver, Hepatocellular Carcinoma
Phase 1UnknownProvectus Biopharmaceuticals, Inc.782009-10-012022-11-02
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Sorafenib, RAD001 - Neuroendocrine Tumor, Carcinoid Tumor
Phase 1CompletedDana-Farber Cancer Institute212009-07-012014-04-29
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
SOM230, RAD001 - Neuroendocrine Tumor, Carcinoid Tumor
Phase 1CompletedDana-Farber Cancer Institute222008-10-012016-10-19
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Ultratrace iobenguane I 131 - Pheochromocytoma, Paraganglioma
Phase 1CompletedMolecular Insight Pharmaceuticals, Inc.242006-06-012011-10-12
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Pasireotide - Carcinoid Tumor, Acromegaly
Phase 1CompletedNovartis Pharmaceuticals852006-06-012020-12-21
Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Seneca Valley Virus (biological agent) - Carcinoid, Neuroendocrine
Phase 1UnknownNeotropix602006-04-012010-02-25
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Dacarbazine and bortezomib - Melanoma, Soft Tissue Sarcoma
Phase 1CompletedVirginia Commonwealth University172004-09-012016-08-18

Narrower conditions

Neuroendocrine Tumors (12)  ·  Adenoma, Islet Cell (4)  ·  Neuroblastoma (3)  ·  Lung Neoplasms (2)  ·  Medulloblastoma (2)  ·  Melanoma (2)  ·  Neoplasms (2)  ·  Paraganglioma (2)  ·  Pheochromocytoma (2)  ·  Sarcoma (2)  ·  Small Cell Lung Carcinoma (2)  ·  Acromegaly (1)  ·  Adrenal Cortex Neoplasms (1)  ·  Adrenocortical Carcinoma (1)

Broader conditions

Adenocarcinoma (20)  ·  Carcinoma (20)  ·  Neoplasms by Histologic Type (20)  ·  Neoplasms, Germ Cell and Embryonal (20)  ·  Neoplasms, Glandular and Epithelial (20)  ·  Neoplasms, Nerve Tissue (20)  ·  Neuroectodermal Tumors (20)  ·  Neoplasms (18)  ·  Neoplasms by Site (10)  ·  Endocrine System Diseases (9)  ·  Endocrine Gland Neoplasms (8)  ·  Neuroendocrine Tumors (8)  ·  Digestive System Diseases (6)  ·  Digestive System Neoplasms (6)  ·  Pancreatic Diseases (6)

Interventions

Everolimus (4)  ·  gallium Ga 68 dotatate (3)  ·  pasireotide (2)  ·  Biological Factors (1)  ·  Bortezomib (1)  ·  Capecitabine (1)  ·  Dacarbazine (1)  ·  Ga(III)-DOTATOC (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Octreotide (1)  ·  Proton Therapy (1)  ·  Radiation (1)  ·  Radiotherapy (1)  ·  Rose Bengal (1)  ·  Sorafenib (1)

Sponsors

Dana-Farber Cancer Institute (2)  ·  Novartis Pharmaceuticals (2)  ·  Arbutus Biopharma Corporation (1)  ·  Guangdong Provincial People's Hospital (1)  ·  Hutchmed (1)  ·  Lale Kostakoglu (1)  ·  M.D. Anderson Cancer Center (1)  ·  Massachusetts General Hospital (1)  ·  Molecular Insight Pharmaceuticals, Inc. (1)  ·  National Cancer Institute (NCI) (1)  ·  Neotropix (1)  ·  Ochsner Health System (1)  ·  Provectus Biopharmaceuticals, Inc. (1)  ·  RayzeBio, Inc. (1)  ·  Sue O'Dorisio (1)

Countries

United States (16)  ·  Canada (2)  ·  Germany (2)  ·  Belgium (1)  ·  China (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Norway (1)

Top investigators

Andrew Poklepovic, MD (1)  ·  Daniel Gomez, MD (1)  ·  Eric Wachter, PhD (1)  ·  Frank I Lin, M.D. (1)  ·  Jennifer Ang Chan, MD, MPH (1)  ·  Jennifer Chan, MD, MPH (1)  ·  Jordan Berlin, M.D. (1)  ·  Lale Kostakoglu, MD, MPH (1)  ·  Marjo Hahka-Kemppinen, MD, PhD (1)  ·  Mark Kowalski, MD (1)  ·  Ralph E Coleman, MD (1)  ·  Rudin Charles, MD, PhD (1)  ·  Sue O'Dorisio, MD (1)

Results publications

PMID 18391430, PMID 22736724, PMID 23475104, PMID 24800725, PMID 28153957, PMID 29181270, PMID 37074571, PMID 39500789

NIH funding

2005 (1)